ABCC1 and ovarian cancer: In the current study, MRP1 was analyzed for docking against several anticancer drugs such as, Paclitaxel, Gemcitabine, Carboplatin, Doxorubicin, and Topotecan which are usually used to treat advanced stage ovarian cancer, to understand drug–target interactions.